Satellos Bioscience Inc.
(MENAFN- Baystreet) 10:09 AM EST - Satellos Bioscience Inc.: Today announced that enrollment has been completed for BASECAMP, the company's Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy in ambulatory boys seven to 10 years of age. Satellos Bioscience Inc.
shares T are trading down $0.12 at $12.08.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment